MEDTE:PA:PA-BNP Paribas Easy ECPI Global ESG Med Tech UCITS ETF EUR Capitalisation (EUR)

ETF | Others |

Last Closing

USD 8.9726

Change

0.00 (0.00)%

Market Cap

N/A

Volume

17.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.31 (-0.68%)

USD 55.36B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-10.60 (-1.94%)

USD 14.29B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-8.61 (-2.20%)

USD 13.82B
WRD:PA HSBC MSCI World UCITS ETF

-0.49 (-1.38%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+2.23 (+0.86%)

USD 9.11B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-8.45 (-1.81%)

USD 8.85B
WLD:PA Lyxor UCITS MSCI World D-EUR

-5.39 (-1.55%)

USD 7.99B
HHH:PA HSBC S&P 500 UCITS ETF

-1.17 (-2.12%)

USD 7.71B
LCWD:PA Multi Units Luxembourg - Lyxor..

N/A

USD 6.91B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

+0.27 (+3.67%)

USD 5.25B

ETFs Containing MEDTE:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.87% 67% D+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.87% 67% D+ 60% D-
Trailing 12 Months  
Capital Gain 2.10% 24% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.10% 21% F 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.65% 26% F 41% F
Dividend Return 2.65% 26% F 40% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 4.31% 89% A- 94% A
Risk Adjusted Return 61.30% 40% F 67% D+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.